AI Terminal
Eckert & Ziegler Strahlen- und Medizintechnik AG
Regulatory Filings • Sep 19, 2025
130_rns_2025-09-19_e4959e3b-dba7-471d-b07b-6e6895e1450e.html
Regulatory Filings
Open in ViewerOpens in native device viewer
News Details
Corporate | 19 September 2025 12:00
Eckert & Ziegler Gains Approval for GalliaPharm® in Japan
Eckert & Ziegler SE / Key word(s): Regulatory Approval/Market Launch
Eckert & Ziegler Gains Approval for GalliaPharm® in Japan
19.09.2025 / 12:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
Berlin, 19 September 2025. Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), a leading provider of isotope technology for nuclear medicine and radiopharmaceutical applications, has received marketing authorization in Japan from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its GalliaPharm® 68 Ge/ 68 Ga Radionuclide Generator, through Novartis Pharma K.K. which will oversee product distribution and safety information management as the Designated Marketing Authorization Holder for GalliaPharm® in Japan.
This authorization opens the door for broader use of Gallium-68–based diagnostics in Japan through the clinical use of the Novartis kit Locametz® for radiopharmaceutical preparation of 68 Ga-PSMA-11, which has also been granted approval.
GalliaPharm® is an established GMP-grade generator for Gallium-68, used internationally in the preparation of radiopharmaceuticals for positron emission tomography (PET) imaging, particularly in enabling PSMA imaging for prostate cancer detection. With the approval now in place, healthcare providers in Japan will be able to access a dependable and proven tool for producing Gallium-68 radiopharmaceuticals, supporting more precise imaging and potentially facilitating earlier diagnosis.
“This regulatory clearance marks a significant step for our medical division,” said Dr. Deljana Werner, Global Director Quality and Regulatory Affairs for the Medical Division of Eckert & Ziegler SE. “Introducing GalliaPharm® to Japan means we can equip local nuclear medicine specialists with the same high-quality generator technology that has supported diagnostic imaging advancements in many other regions.”
The entry of GalliaPharm® into Japan reflects Eckert & Ziegler’s ongoing commitment to expanding access to reliable isotope technologies, tailored to the requirements of local markets, and to fostering innovation in molecular imaging worldwide.
About Eckert & Ziegler SE
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler SE shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
**Contributing to saving lives.
Contact**
Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
[email protected] / [email protected]
Tel.: +49 (0) 30 / 94 10 84-138; https://ezag.com
19.09.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | Eckert & Ziegler SE |
| Robert-Rössle-Str.10 | |
| 13125 Berlin | |
| Germany | |
| Phone: | +49 30 941084-138 |
| Fax: | +49 30 941084-0 |
| Internet: | www.ezag.de |
| ISIN: | DE0005659700 |
| WKN: | 565970 |
| Indices: | SDAX, TecDax, |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2199468 |
| End of News | EQS News Service |
2199468 19.09.2025 CET/CEST